Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$56.5 million.

  • Regenxbio's Free Cash Flow fell 3810.64% to -$56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.3 million, marking a year-over-year increase of 4247.07%. This contributed to the annual value of -$175.6 million for FY2024, which is 2312.33% up from last year.
  • As of Q3 2025, Regenxbio's Free Cash Flow stood at -$56.5 million, which was down 3810.64% from -$49.7 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Free Cash Flow registered a high of $326.9 million during Q4 2021, and its lowest value of -$85.7 million during Q1 2023.
  • Its 5-year average for Free Cash Flow is -$30.6 million, with a median of -$50.8 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Regenxbio's Free Cash Flow was 112985.44% (2021), while the steepest drop was 12569.63% (2021).
  • Regenxbio's Free Cash Flow (Quarter) stood at $326.9 million in 2021, then tumbled by 113.72% to -$44.8 million in 2022, then increased by 6.59% to -$41.9 million in 2023, then increased by 21.92% to -$32.7 million in 2024, then tumbled by 72.62% to -$56.5 million in 2025.
  • Its Free Cash Flow stands at -$56.5 million for Q3 2025, versus -$49.7 million for Q2 2025 and $32.6 million for Q1 2025.